Drug intelligence / Profile preview

EMP116

Development stage: Preclinical
Lead developer: Empiriko
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**EMP116** is an Empiriko preclinical PSMA-targeted radio-chemotherapy program for prostate cancer. It is described as a theranostic therapeutic paired with the gallium-68 diagnostic tracer EMP102-Dx and is designed to combine targeted **lutetium-177** radiotherapy with a chemotherapeutic component delivered through Empiriko's RCV platform. By binding prostate-specific membrane antigen on prostate cancer cells, EMP116 is intended to localize radiation and chemotherapy to PSMA-expressing tumors.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on EMP116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP116.

Explore the full profile